Alerta

SENSOR APPLICATOR ASSEMBLY FOR CONTINUOUS GLUCOSE MONITORING SYSTEM

Resumen de: US2025152103A1

Provided is a sensor applicator assembly for a continuous glucose monitoring system and provides a sensor applicator assembly for a continuous glucose monitoring system, which is manufactured with a sensor module assembled inside an applicator, thereby minimizing additional work by a user for attaching the sensor module to the body and allowing the sensor module to be attached to the body simply by operating the applicator, and thus can be used more conveniently. A battery is built in the sensor module and a Separate transmitter is connected to the sensor module so as to receive power supply from the sensor module and be continuously used semi-permanently, thereby making the assembly economical. The sensor module and the applicator are used as disposables, thereby allowing accurate and safe use and convenient maintenance.

WEARABLE DEVICE MEASURING BLOOD GLUCOSE LEVELS BASED ON GLUCOSE REFLECTIVITY

Resumen de: US2025152046A1

The blood glucose detector (BGD) is placed on user's wrist, ear, nose, or other skin surface, at a NIR light infiltration location to detect arterial blood flow. Earlier-obtained baseline BG data is obtained via BGD and conventionally-obtained BG data. The user-wearable housing or body-mounted BGD system includes processor, memory, and NIR transmitter/sensor. BG baseline data is stored in memory. The NIR transmitter/sensor disposed on infiltration location. In detection, transmitter generates light in predetermined narrow band within NIR range 1350-1800 nm. Sensor detects reflected light from arterial BG as then-detected BG signal. Memory stores a subcutaneous interference factor (SIF) contributory value for NIR narrow band. Onboard processor (or smart phone APP) correlates the detected BG signal with the baseline as modified by the SIF value and generates displayable BG level to user via user-wearable housing or the user interface display on the smart phone as connected to body-mounted BGD system.

HEALTH ANALYSIS METHOD AND APPARATUS, ELECTRONIC DEVICE AND STORAGE MEDIUM

Resumen de: US2025152048A1

The present disclosure discloses to a health analysis method for blood glucose management, a health analysis apparatus for blood glucose management, an electronic device and a storage medium. The health analysis method includes: obtaining a plurality of blood glucose data of a user during a detection time period, wherein the plurality of blood glucose data include a current blood glucose value detected at a current moment; determining a time in range ratio of the user according to the plurality of blood glucose data and a glucose standard range; predicting a time when a blood glucose value of the user meets the glucose standard range and a time when the time in range ratio meets a qualified condition according to the current blood glucose value and the time in range ratio; and analyzing predicted results to provide a blood glucose prediction curve to the user.

HEALTH-MONITORING MEASUREMENT AND/OR MONITORING WITH A SMARTWATCH THAT INCLUDES ONE OR MORE VCSEL'S

Resumen de: US2025152045A1

A glucose detection or monitoring system that includes a VCSEL laser with one or more active regions having quantum wells and barrier. The active regions are surrounded by one or more p-n junctions. The one or more active regions can include a selected shape structure, and one or more tunnel junctions (TJ). One or more apertures are provided with the selected shape structure, one or more buried tunnel junctions (BTJ) or oxide confine apertured, additional TJ's, planar structures and or additional BTJ's created during a regrowth process that is independent of a first growth process with a VCSEL output determined in response to a monitoring application of the VCSEL, the VCSEL having an HCG grating and a bottom DBR. A housing of a smartwatch interior houses the VCSEL laser. The smartwatch includes one or more of a display, an optical sensor, one or more electrodes, SIM card slot, speaker, microphone, charging pins, and a band.

GLUCOSE DIFFUSION CONTROL LAYER SOLUTION FOR CONTINUOUS BLOOD GLUCOSE-MEASURING BIOSENSOR, GLUCOSE DIFFUSION CONTROL LAYER FOR CONTINUOUS BLOOD GLUCOSE-MEASURING BIOSENSOR COMPRISING SAME, AND CONTINUOUS BLOOD GLUCOSE-MEASURING BIOSENSOR COMPRISING SAME

Resumen de: US2025152049A1

The present invention relates to a glucose diffusion control layer solution for a continuous blood glucose-measuring biosensor, a glucose diffusion control layer for a continuous blood glucose-measuring biosensor, comprising the same, and a continuous blood glucose-measuring biosensor comprising the same. More specifically, the present invention relates to: a glucose diffusion control layer solution for a continuous blood glucose-measuring biosensor, in which, by using only a substance of which biocompatibility has been verified, stability can be ensured even when injected into the human body, and glucose permeability and water absorbance can be controlled; a glucose diffusion control layer for a continuous blood glucose-measuring biosensor, comprising the same; and a continuous blood glucose-measuring biosensor comprising the same.

PHARMACEUTICAL FORMULATIONS

Resumen de: US2025152673A1

Disclosed herein are an aqueous pharmaceutical formulation comprising cagrilintide and an aqueous formulation comprising semaglutide. The compositions of these two pharmaceutical formulations allow for their presentation in, and administration using, the dual-chamber medical device disclosed herein. Individuals with diseases, such as diabetes and/or obesity and/or related co-morbidities, may benefit from the co-administration of semaglutide and cagrilintide, and/or of the two liquid pharmaceutical formulations disclosed herein, using the medical device disclosed herein.

TIME AVERAGED BASAL RATE OPTIMIZER

Resumen de: US2025152817A1

Systems and methods for integrating a continuous glucose sensor, including a receiver, a medicament delivery device, a controller module, and optionally a single point glucose monitor are provided. Integration may be manual, semi-automated and/or fully automated.

DEVICE FOR DELIVERING INSULIN WITH BASEPLATE AND INTEGRATED MEMS MICROPUMP AND PRESSURE SENSOR

Resumen de: US2025152808A1

A device for delivering medicament to a user, the device configured to be mounted to the user, the device including a baseplate comprising: a first opening and second opening to align with a first port and second port of a micropump, respectively; a first fluid channel in fluid communication with the second opening of the baseplate; and a platform for receiving a pressure sensor, the platform having an opening that communicates with the first fluid channel to enable the pressure sensor to sense pressure in the fluid channel.

DIABETES THERAPY BASED ON DETERMINATION OF FOOD ITEM

Resumen de: US2025152814A1

Techniques for therapy delivery for diabetes treatment are provided. In some embodiments, the techniques may involve identifying an object as a food item based on a representation of the object. In some embodiments, the techniques may involve generating nutrition information or volume information of the food item. The techniques may involve determining that the nutrition information or the volume information of the food item exceeds a threshold. The techniques may involve determining that the patient's glucose level will rise based on the determination the nutrition information or the volume information of the particular food item exceeds the threshold. The techniques may involve generating therapy information for a patient based on the determination that the patient's glucose level will rise. The techniques may involve automatically administering insulin to the patient to cause the glucose level of the patient to lower to within a predetermined range and based on the therapy information.

INTEGRATED INSULIN DELIVERY SYSTEM WITH CONTINUOUS GLUCOSE SENSOR

Resumen de: US2025152816A1

Systems and methods for integrating a continuous glucose sensor 12, including a receiver 14, a medicament delivery device 16, a controller module, and optionally a single point glucose monitor 18 are provided. Integration may be manual, semi-automated and/or fully automated.

ANALYTE SENSORS AND SENSING METHODS FOR DUAL DETECTION OF GLUCOSE AND ETHANOL

Resumen de: EP4552565A1

Multiple enzymes may be present in one or more active areas of an electrochemical analyte sensor for detecting one or more different analytes. In particular, an analyte sensor may comprise a sensor tail configured for insertion into a tissue and one or more working electrodes having a glucose-responsive active area and an ethanol-responsive active area to detect glucose and ethanol in vivo.

BODY ATTACHMENT UNIT FOR CONTINUOUS BLOOD GLUCOSE MEASUREMENT

Resumen de: EP4552558A2

The present disclosure relates to a body attachment unit for continuous blood glucose measurement, in which the body attachment unit is manufactured so as to be assembled in an applicator, thereby minimizing additional work and allowing attachment of the body attachment unit to a body simply by operation of the applicator. In particular, a wireless communication chip is provided in the body attachment unit to enable communication with an external terminal, thereby enabling simple and convenient use without performing additional work of connecting a separate transmitter, and allowing easier maintenance. In addition, activation occurs by a user's operation after the body attachment unit is attached to the body, such that an activation start point in time can be adjusted to an appropriate point in time according to the user's needs, and activation occurs in a stabilized state, thereby providing the body attachment unit allowing more accurate blood glucose measurement.

INSULIN PUMP WITH INTEGRATED CONTINUOUS GLUCOSE MONITOR

Resumen de: US2024189504A1

Embodiments disclosed herein are directed to ambulatory infusion pump systems that integrate a CGM sensor with an ambulatory infusion pump. An electrical connection can be established between the CGM sensor and the pump such that no wireless connectivity between the devices is required.

SYSTEM FOR PROVIDING ALERTS OPTIMIZED FOR A USER

Resumen de: EP4552567A1

Systems and methods are disclosed that provide smart alerts to users, e.g., alerts to users about diabetic states that are only provided when it makes sense to do so, e.g., when the system can predict or estimate that the user is not already cognitively aware of their current condition, e.g., particularly where the current condition is a diabetic state warranting attention. In this way, the alert or alarm is personalized and made particularly effective for that user. Such systems and methods still alert the user when action is necessary, e.g., a bolus or temporary basal rate change, or provide a response to a missed bolus or a need for correction, but do not alert when action is unnecessary, e.g., if the user is already estimated or predicted to be cognitively aware of the diabetic state warranting attention, or if corrective action was already taken.

ANALYTE SENSORS AND SENSING METHODS FOR DETECTING CREATININE

Resumen de: EP4552566A1

Creatinine levels may be monitored as a measure of kidney function. Conventionally, blood and/or urine tests are used for this purpose. Analyte sensors capable of monitoring creatinine in vivo may comprise: a sensor tail comprising at least a first working electrode, a creatinine-responsive active area disposed upon a surface of the first working electrode, a first membrane that is permeable to creatinine and overcoats the creatinine-responsive active area, and an oxygen scavenger located upon the sensor tail in proximity to the creatinine-responsive active area. The creatinine-responsive active area comprises a first electron transfer agent, a first polymer, and an enzyme system comprising multiple enzymes, particularly creatinine amidohydrolase, creatine amidohydrolase, and sarcosine oxidase, that are capable of acting in concert to facilitate detection of creatinine. An oxidase enzyme may serve as the oxygen scavenger, particularly glucose oxidase when detecting creatinine in fluids also containing glucose.

SENSOR APPLICATOR ASSEMBLY FOR CONTINUOUS GLUCOSE MONITORING SYSTEM

Resumen de: US2025143643A1

The present invention relates to a sensor applicator assembly for a continuous glucose monitoring system and provides a sensor applicator assembly for a continuous glucose monitoring system, which is manufactured with a sensor module assembled inside an applicator, thereby minimizing additional work by a user for attaching the sensor module to the body and allowing the sensor module to be attached to the body simply by operating the applicator, and thus can be used more conveniently. A battery is built in the sensor module and a separate transmitter is connected to the sensor module so as to receive power supply from the sensor module and be continuously used semi-permanently, thereby making the assembly economical. The sensor module and the applicator are used as disposables, thereby allowing accurate and safe use and convenient maintenance.

ANIMAL MONITORING AND CARE SYSTEM

Resumen de: WO2025093787A1

The present invention relates to a system that remotely monitors the health status and behaviour of an animal by means of an implanted device. The device collects data such as temperature, heart rate, glucose levels and movement of the animal. Furthermore, the invention includes RFID technology to identify the animal, which allows identification data to be stored and transmitted together with the health data. The invention uses NFC and RFID wireless technologies to transmit all this information to a smartphone or another terminal, wherein the data can be stored and analysed in the cloud. The solution is ideal for animals that are not able to wear collars or external devices, improving their safety and comfort.

INTEGRATED MEDICAMENT DELIVERY DEVICE FOR USE WITH CONTINUOUS ANALYTE SENSOR

Resumen de: US2025148667A1

An integrated system for the monitoring and treating diabetes is provided, including an integrated receiver/hand-held medicament injection pen, including electronics, for use with a continuous glucose sensor. In some embodiments, the receiver is configured to receive continuous glucose sensor data, to calculate a medicament therapy (e.g., via the integrated system electronics) and to automatically set a bolus dose of the integrated hand-held medicament injection pen, whereby the user can manually inject the bolus dose of medicament into the host. In some embodiments, the integrated receiver and hand-held medicament injection pen are integrally formed, while in other embodiments they are detachably connected and communicated via mutually engaging electrical contacts and/or via wireless communication.

SENSOR WITH POROUS WICKING LAYER

Resumen de: US2025146043A1

The present invention relates to organic thin film sensors and the preparation and use thereof in sensing applications, and in particular in glucose sensing applications.

APPLICATOR FOR CONTINUOUS BLOOD GLUCOSE MEASUREMENT

Resumen de: US2025143605A1

Provided are a continuous blood glucose measurement device and an applicator, wherein the continuous blood glucose measurement device is produced in a state in which a body attachment unit has been assembled inside an applicator, so as to minimize a user's additional work of attaching the body attachment unit to the body, thereby enabling the body attachment unit to be attached to the body only by simply activating the applicator. Particularly, the present invention provides a continuous blood glucose measurement device and an applicator, wherein the continuous blood glucose measurement device: includes a wireless communication chip in a body attachment unit so as to enable communication with an external terminal, thereby enabling simple and convenient use thereof, without additional work for connecting a separate transmitter, and easier maintenance; and is activated by a user's operation after the body attachment unit is attached to the body.

SYSTEM AND METHODS FOR DETERMINING HEALTH-RELATED METRICS FROM COLLECTED PHYSIOLOGICAL DATA

Resumen de: US2025143591A1

Techniques and systems include predicting various health conditions using a photoplethysmography (PPG) signal or a video signal based on images of a patient's fingertip or other body portion captured using a mobile device. The video signal may be transformed into a pseudo PPG signal to measure blood volume changes in the patient's blood flow to derive data indicating a disease state or health-related characteristic, such as blood oxygen level, blood glucose level, heart rate variability, hemoglobin, respiration rate, or arrhythmia. Techniques involve real-time environment assessment and problematic issue detection, training an artificial intelligence (AI) model to measure signal quality so as to select high-quality signals from a range of signals, and domain adaption and transfer learning to make use of publicly available datasets.

METHOD AND SYSTEMS FOR INTER-APPLICATION USER INTERFACE GENERATION

Resumen de: WO2025093560A1

A method for generating diabetes management parameter user interfaces includes providing stored program instructions of a first diabetes management application (DMA), the first DMA configured to be stored in a memory of an electronic device and, upon execution by a processor, the first DMA is configured to generate a first output display of a plurality of diabetes management parameters corresponding to a time series of analyte data, the plurality of diabetes management parameters depicting a trend of diabetes management parameter levels over time, generate a graphical indicator of a link to a second DMA stored in the memory, and activate the second DMA in response to an input selection of the link, wherein the second DMA is configured to be executed by the processor to generate a second output display of a current-time diabetes management parameter corresponding to the time series of the analyte data stored in the memory.

CONTINUOUS BLOOD GLUCOSE MEASUREMENT APPARATUS

Resumen de: US2025143606A1

Provided relates to a continuous blood glucose measurement device which is produced with an assembled body attachment unit inside an applicator so as to minimize a user's additional work of attaching the body attachment unit to the body, thereby enabling the body attachment unit to be attached to the body by simply activating the applicator, and which is provided with a wireless communication chip in a body attachment unit so as to enable communication with an external terminal, thereby enabling simple and convenient use, without additional work of connecting a separate transmitter, and easier maintenance; and is activated by the user after the body attachment unit is attached to the body so as to enable the operation start time to be adjusted to an appropriate time according to user's needs, and to enable the operation to start in a stabilized state so that blood glucose can be measured more accurately.

CONTINUOUS GLUCOSE MONITORING SYSTEM

Resumen de: US2025144296A1

Methods and systems for delaying alarms that include detecting an analyte level using an analyte sensor; and delaying the annunciation of an analyte alarm after the analyte level crosses an analyte threshold, wherein the delay is based on one or both of (1) a magnitude of difference between the analyte level and the analyte threshold and (2) a duration of time in which the analyte level has crossed the analyte threshold.

SYSTEMS AND METHODS FOR IMPEDIMETRIC GLUCOSE SENSING USING BORONIC ACID VIOLOGEN (OBBV)

Nº publicación: US2025143609A1 08/05/2025

Solicitante:

MEDTRONIC MINIMED INC [US]
Medtronic MiniMed, Inc